Streptococcus pneumoniae Attenuated Strain SPY1 with an Artificial Mineral Shell Induces Humoral and Th17 Cellular Immunity and Protects Mice against Pneumococcal Infection

Xinyuan Zhang1†, Jingjing Cui2†, Yingying Wu1†, Hong Wang1, Jian Wang1, Yulan Qiu1, Yunjun Mo1, Yujuan He1, Xuemei Zhang1, Yibing Yin1 and Wenchun Xu1*

1Key Laboratory of Laboratory Medical Diagnostics Designated by the Ministry of Education, School of Laboratory Medicine, Chongqing Medical University, Chongqing, China, 2Department of Clinical Laboratory, Chongqing Hospital for Women and Children, Chongqing, China

Streptococcus pneumoniae is a major pathogen leading to substantial morbidity and mortality in children under 5 years of age. Vaccination is an effective strategy to prevent S. pneumoniae infection. SPY1 is a pneumococcal vaccine candidate strain obtained in our previous study. To improve its stability and immunogenicity, in this study, we constructed the SPY1ΔlytA strain that lacks autolysin activity and was coated with an artificial exterior surface calcium phosphate shell by in situ mineralization. The resulting strain SPY1ΔlytA CaPi displayed enhanced thermal stability enabling storage at 37°C for 1 week. Furthermore, mucosal and subcutaneous immunization with the SPY1ΔlytACaPi strain induced better protective effects than SPY1ΔlytA in anti-colonization after challenging with 19F and anti-invasion by D39 in mice. Subcutaneous immunization with SPY1ΔlytACaPi elicited higher IgG level while mucosal immunization primarily elicited an immune response which is supposed to be related to Th17 cells. Taken together, the mineralized strain may be a promising candidate for an attenuated S. pneumoniae vaccine.

Keywords: Streptococcus pneumoniae, live attenuated vaccine, biomineralization, thermal stability, immunogenicity

INTRODUCTION

Streptococcus pneumoniae is a major cause of pneumonia, otitis media, sepsis, and meningitis in children and the elderly (1). Vaccination is an effective strategy to prevent S. pneumoniae infection, the 23-valent pneumococcal polysaccharide vaccine and protein-conjugate vaccines (PCV) are currently in use including PCV7, PCV9, PCV10, and PCV13 (2–4). However, these vaccines have some disadvantages including weak immunogenicity, limited serotype coverage, serotype replacement, and high cost (5, 6). Therefore, developing a new and more ideal pneumococcal vaccine has become an important goal.
**Streptococcus pneumoniae** vaccine development includes whole-cell, polysaccharide, polysaccharide conjugate, as well as subunit protein vaccines. *S. pneumoniae* is highly diverse genetically and can rapidly change itself by recombination. A protein that is not essential for viability but significant in immunological recognition by the host can be altered or eliminated (*pspA* and *pspP*) (7). Candidate vaccines combining several common proteins may reduce the possibility that pneumococcus would readily evolve to evade immunity induced by vaccination. Generally, soluble antigen vaccines tend to lead host immune tolerance while bacteria-like particles including diversity antigens and agonists of toll-like receptors can activate multiple Toll-like receptors to induce stronger immune responses (8). Therefore, an attenuated live vaccine would be an ideal candidate to protect against pneumococcal infection.

SPY1 is a live attenuated strain of *S. pneumoniae* with significantly reduced amounts of capsular polysaccharide and pneumolysin (9). SPY1 can induce Th1/Th2/Th17 immune responses and protect mice against pneumococcal infection (10). SPY1 also offer better protection effect than the commercial 23-valent polysaccharide vaccine and therefore is a candidate vaccine strain (9). However, because of the weak immunogenicity of SPY1, it must be given with an adjuvant such as cholera toxin (CT) that is toxic for humans (11).

For vaccine, maintaining the cold chain is critical for adequate bioactivity. Despite preservation at low temperature, nearly half of the amount of vaccine was estimated to be abandoned around the world due to heat inactivation. And the cost of refrigeration contributes to about 80% of the cost of vaccine (12). Biological mineralization technology has been successfully used to improve thermal stability of living organisms (13–19). This technique involves the use of calcium phosphate to form an eggshell-like exterior that has improved the thermal stability and immunogenicity of viruses and yeast (17–19). A vaccine virus treated in this manner can be stored at 26°C for more than 9 days and at 37°C for 1 week (19). However, there are no reports of biomineralization used for live bacterial vaccines. In order to improve the thermal stability of SPY1 and further enhance its immunogenicity, this study focused on the *in situ* mineralization of SPY1 and evaluated its immune protection effects.

**MATERIALS AND METHODS**

**Mice**
6- to 8-week-old C57BL/6 female mice were obtained from the animal center of Chongqing Medical University. Mice were kept under specific pathogen-free conditions at the animal centers of Chongqing Medical University during the time of the experiments.

**Bacteria Strains**
*Streptococcus pneumoniae* strain NCTC 7466 (D39, serotype 2) was obtained from the National Collection of Type Cultures (NCTC; London, United Kingdom). *S. pneumoniae* clinical isolates CMCC 31693 (serotype 19F) were obtained from the National Center for Medical Culture Collections (CMCC; Beijing, China). The *S. pneumoniae* SPY1 strain used in this study was obtained previously and stored in 20% glycerol at −80°C (10). All *S. pneumoniae* strains were grown on Columbia sheep blood agar plates or in casein-based medium with yeast extract (C+Y medium) at 37°C under 5% CO2 atmosphere. Zeta potential were measured by Malvern Zetasizer when SPY1 and SPY1ΔlytA were suspended in sterility phosphate-buffered saline (PBS) at pH 7.2.

**SPY1ΔlytA Strain Construction**
We constructed an attenuated *S. pneumoniae* strain SPY1ΔlytA by insertional inactivation. The plasmid pEVP3 were constructed with a *lytA* homologous arm was transformed into SPY1 and integrated into the *lytA* gene by homologous recombination (20). Primers *lytA*-ins F and *lytA*-ins R were designed by Primer Premiers 5 according to the sequence of the *S. pneumoniae* D39 *lytA* gene (**Table 1**). The *lytA*-ins gene was integrated into the plasmid pEVP3 (21) and pEVP3-lytA-ins was inserted into the SPY1 *lytA* gene using insertional inactivation (20). The SPY1ΔlytA mutant strain was screened on blood plates containing erythromycin (0.25 μg/ml) and chloramphenicol (2.5 μg/ml). PCR were used to confirm the mutation in chloramphenicol resistant isolates (**Table 1**). To evaluate the production of LytA protein in SPY1ΔlytA mutant strain, the expression of LytA was analyzed by Western blotting with anti-LytA sera.

**Biomineralization of SPY1ΔlytA**
The SPY1ΔlytA mutant was cultured in C + Y liquid medium to mid-exponential growth phase (OD600 = 0.4–0.5, 1.5 × 10⁶ CFU/mL) and washed twice with 0.9% NaCl by centrifuging at 12,000 rpm for 5 min. The cell density was then adjusted to 1 × 10⁶ CFU/mL in normal saline. The bacterial suspension was added to 5 ml of a 10 mM CaCl2 solution and placed at 4°C for 1 h. The mixture was then centrifuged 10–15 min at 2,000 rpm and the supernatant was removed. The pellets were suspended with equal volumes of 4, 6, and 10 mM Na2HPO4 (pH 6.8) and centrifuged 5 min at 3,000 rpm. The pellets were washed and suspended in sterile saline. Bacteria were visualized using scanning electron microscope (SEM, Model S-3000N, Hitachi, Japan).

**Immunization and Challenge**
SPY1 and SPY1ΔlytA were grown at 37°C in 5% CO2 in C+Y medium to approximately 1.5 × 10⁶ CFU/ml. The cells were collected by centrifugation, washed twice, and suspended in

**TABLE 1 |** The primers of amplification and identification of SPY1ΔlytA mutant strain.

| Primer | Sequence (5′→3′) | Length (bp) |
|--------|------------------|-------------|
| *lytA*-ins F | GAAGATCTAGATTGCGCTCAAGTGCG | 421 |
| *lytA*-ins R | GGGCGCGGAAGGTGACAACTGTTGTTGA | 6,723 |
| *lytA* Fexp BamH I | CCTCGAGATATGAAATTAATGTGAGTAAAT | 1,068 |
| *lytA* Rexp Xho I | CCGCTCGAGTTTTACTGTAATCAAGCCATC | 1,416 |
| pEVP3 F | ATCTCAGTTCGGTGTAGGTC | 1,068 |
| pEVP3 R | TTATTGGGATAAGTTAGAGCC | 1,416 |
| ply F | ATGCGAAATTAACAGAATTGACT | 1,068 |
| ply R | CTAGTCATTTTCTACATTCCCTTCT | 1,416 |
sterile PBS. For mucosal immunization, the mice were randomly divided into six groups: PBS, CT (Sigma-Aldrich), SPY1, SPY1ΔlytA, SPY1ΔlytA + CT, and SPY1ΔlytACaPi. Similarly, we divided the mice into six groups for subcutaneous immunization using: PBS, alum adjuvant (alum; Thermo Fisher Scientific), SPY1, SPY1ΔlytA, SPY1ΔlytA + alum, and SPY1ΔlytACaPi. The experimental groups were vaccinated either subcutaneously with 100 µl SPY1 (1 × 10⁸ CFU) mixed with equal volume of alum adjuvant or via the mucosa with SPY1 (1 × 10⁸ CFU) plus 1 µg CT in 30 µl PBS. For subcutaneous immunization, mice were vaccinated three times over 2 weeks, whereas for mucosal immunization, mice were immunized once per week for four consecutive weeks. Serum samples were collected 1 week after the final immunization. Blood samples were collected from tails. All samples were stored at −80°C.

For the colonization model, 2 weeks after the last vaccination, mice were anesthetized and challenged with 1 × 10⁸ CFU of pneumococcal strain CMCC 31693 (serotype 19F) and sacrificed 72 h later. CFU counts in nasal washes and lung homogenates were determined as previously described (22). For the lethal intranasal challenge model, C57BL/6 mice were anesthetized and then inoculated intranasally with pneumococcal strain NCTC 7466 (D39, serotype 2; 1 × 10⁶ CFU) in 30 µl of PBS. Survival was monitored for 21 days.

**Antibody Titers and IgG IsoType Determinations**

Protein concentrations were determined by BCA protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China) and adjusted to equal protein concentrations. For measurement of antigen specific IgG titers, antibody levels were determined by using 96-well plates coated with SPY1 as previously described (22, 23).

**Cytokine Measurements**

One week after the final immunization, mouse splenocytes were isolated (24) and transferred into 24-well tissue culture plates (2 × 10⁶ cells/well) in 1 ml of DMEM with 10% fetal calf serum (HyClone). Then, cells were treated for 72 h with Concanavalin A (5 mg/ml, Sigma, St. Louis, MO, USA) or 70% ethanol-killed SPY1 (equivalent to 10⁶ CFU/ml). Cytokines IFN, IL-4, IL-10, and IL-17A in the culture supernatants were determined using commercial kits (Biolegend, CA, USA) according to the manufacturer’s recommendations.

**Statistical Analysis**

Data were compared using Student’s t test or a Mann–Whitney U test. Survival rates were analyzed with a log-rank test. Differences at a P value of <0.05 were considered significant. Statistical analysis was performed using GraphPad Prism, version 5.

**RESULTS**

**SPY1ΔlytA Strain Construction**

An interesting characteristic of Streptococcus pneumoniae, autolysis, is highly related to LytA protein (25). In order to avoid bacterial autolysis during mineralization, non-autolysis SPY1 strain (SPY1ΔlytA) was constructed by insertional inactivation method.

Due to the erythromycin resistance of SPY1 and CAT gene from the introduced pEVP3 plasmid, blood agar plates supplemented with appropriate antibiotics were used to screen out...
the correctly constructed mutant strain SPY1ΔlytA (Figure 1A). Besides, SPY1ΔlytA strain was authenticated with PCR. The amplified fragment lytA-ins (lane 3) refers to the correct insertion of lytA homologous arm into the SPY1 strain. No lytA fragments were amplified (lane 4) and amplified pEVP3 fragment (lane 5) indicated that the pEVP3 vector was integrated into SPY1 chromosome and disrupted lytA gene (Figure 1B). Western blot revealed that LytA was knocked out in SPY1ΔlytA (Figure 1C). In conclusion, LytA has been silenced in the SPY1ΔlytA strain.

**SPY1ΔlytA Strain Lacks Autolysis Ability**

Autolysis is an important feature of *S. pneumoniae* and LytA protein is essential to it (25). After lytA inactivation, the autolysis ability was measured. During culturing in C + Y medium, the OD_{620} of SPY1 increased gradually to about 1.0 and then decreased rapidly, while the OD_{620} of SPY1ΔlytA increased to about 1.0 and could maintain for 36 h (Figure 2A). The SPY1 bacterial suspension became clear at 12 h, while the SPY1ΔlytA bacterial suspension was still cloudy (Figure 2B).

Gram stains of SPY1 and SPY1ΔlytA cultured in C + Y liquid medium for 4 h indicated the morphology of these two bacteria was similar: Gram-positive, spearhead-like and in pairs or short chain-like arrangements. After 12 h and up to 36 h, SPY1 was not visible in stained preparations of culture medium. However, SPY1ΔlytA cultures were similar to the 4 h samples at these later times. Cultures of SPY1ΔlytA for 24–36 h varied to round and abnormally form (Figure 2C). Together, these data indicated that we had successfully inactivated the autolysin function of SPY1.

**In Situ Mineralization of SPY1ΔlytA**

The bacterial strain SPY1 lacks capsule and therefore exposes other surface components such as teichoic acids. Zeta potential showed that SPY1 and SPY1ΔlytA present a net negative surface charge (−14.97 ± 0.75 and −15.2 ± 0.82, respectively), which enabled coating with calcium phosphate by *in situ* mineralization. The SPY1ΔlytA strain was treated with calcium-rich physiological saline to obtain a calcium-rich surface layer that acted as a nucleation site. Disodium hydrogen phosphate was then titrated into the calcium-rich SPY1ΔlytA suspension to obtain a CaPi mineralized surface layer (Figure 3A). SEM indicated that the optimum phosphate concentration for SPY1ΔlytA CaPi
**FIGURE 3** | Construction of SPY1 ΔlytACaPi.
(A) Schematic diagram of the *in situ* mineralization process of SPY1 ΔlytA. (B) Scanning electron microscope images of CaP-mineralized SPY1 ΔlytA after titration with phosphate solution in different concentrations. The native SPY1 ΔlytA strain was used as control. (C) Mineral shells surrounding SPY1 ΔlytA. (a–c) SPY1 ΔlytA was stained with Gram staining. (d–f) the mineral shells was stained with tetracycline hydrochloride and observed under UV light (360–370 nm).
was 6 mM (Figure 3B). Tetracycline hydrochloride was used to characterize the calcium phosphate shell (Figure 3C), for it being able to bind with calcium ions to induce a golden-yellow fluorescence under UV light (360–370 nm). These results confirmed that SPY1ΔlytACaPi was successfully constructed.

The Mineralized Layer Improved the Thermal Stability of SPY1ΔlytA at 37°C
Thermal stability was determined by detecting bacterial viability at different time points after incubation at 37°C. The viability of SPY1ΔlytACaPi was significantly greater than both SPY1 and SPY1ΔlytA (Figure 4).

Vaccination with SPY1ΔlytACaPi Induced Strong Immune Response in Mice
We examined the humoral and cellular immune responses of mice immunized mucosally and subcutaneously with SPY1ΔlytACaPi. In subcutaneous-vaccinated mice, antigen-specific IgG levels of SPY1ΔlytACaPi group were significantly higher than those of other groups. However, in mucosally vaccinated mice, IgG levels of SPY1ΔlytACaPi group were similar to controls (Figure 5A).

In mucosally vaccinated mice, levels of IL-17A and IL-10 produced by splenocytes of mice immunized with SPY1ΔlytACaPi were significantly higher than SPY1ΔlytA (Figure 5B). The elevation of cytokine in SPY1ΔlytACaPi equals to which in SPY1ΔlytACaPi + CT group, suggesting the mineralized vaccine strain had an adjuvant effect. However, the subcutaneous immunization of the mineralized vaccine strain SPY1ΔlytACaPi did not result in elevated levels of IFN-γ, IL-4, IL-17A, and IL-10 (Figure 5C). These results suggested the immune responses induced by SPY1ΔlytACaPi mucosal vaccination may be mediated by Th17 and Treg cells, while subcutaneous immunization stimulated humoral immune responses.

Immunization with SPY1ΔlytACaPi Reduced Pneumococcal Colonization
Nasopharyngeal colonization represents the initial step of invasive pneumococcal infection (26). The bacterial loads of mice mucosally or subcutaneously immunization challenged intranasally with S. pneumoniae strain 19F were measured by CFU counting. Nasal CFU counts in the SPY1 and SPY1ΔlytA vaccinated mice groups were not significantly different, which indicated that the deletion of the LytA protein did not affect the immunogenicity of SPY1. The bacterial loads for the mineralized vaccine SPY1ΔlytACaPi group were significantly lower than the non-mineralized vaccine SPY1ΔlytA group, while it is similar to which of non-mineralized vaccine groups in the presence of adjuvants (SPY1ΔlytA + CT or SPY1ΔlytA + alum) (Figures 6A,B). These results suggested that the mineralized shells had adjuvant effects both in mucosal and subcutaneous vaccinations and that mineralized strain vaccination reduced pneumococcal colonization.

Immunization with SPY1ΔlytACaPi Provided Protection against Pneumococcal Lethal Infections
To evaluate the protective effects of SPY1ΔlytACaPi vaccination against lethal infection of pneumococci, mice were challenged intranasally with S. pneumoniae strain D39 at 1 × 10⁶ CFU/mouse 2 weeks after last immunization. The mice survival rates for mucosal vaccination using SPY1ΔlytACaPi were significantly higher than that of SPY1ΔlytA (Figure 7A). Similarly, the mice survival rates for subcutaneously vaccination using SPY1ΔlytACaPi were higher than that of SPY1ΔlytA, but did not reach statistical significance (Figure 7B). In short, the mineralized strain vaccination could provide a better protective effect against pneumococcal infections than the non-mineralized strain.

DISCUSSION
SPY1 is a live attenuated S. pneumoniae strain and a vaccine candidate strain because it can elicit strong protective effects against S. pneumoniae challenges in mice (9, 10). However, the autolysis of the strain prevents its growth to the end of the logarithmic growth phase. This property limits the potential of SPY1 as a vaccine strain. We therefore inactivated lytA and the strain SPY1ΔlytA maintained unbroken cell shapes for an extended period indicating the autolysis property was eliminated. This made the strain more stable for storage and transport than the parent SPY1.

The instability of the vaccine products and inactivation of vaccines during storage and transportation have seriously hampered their effectiveness. The strain SPY1ΔlytA also needed to be cryopreserved. Mineralized vaccines can be stored at 37°C for more than 7 days and can stimulate higher antibody production after immunization (19). Therefore, we intended to improve the thermal stability and immunogenicity of SPY1ΔlytA by mineralization treatment.

The surface of SPY1 lacks a capsule and surface components such as teichoic acid are exposed. When SPY1ΔlytA is cultured
FIGURE 5 | Continued
We evaluated the immune protective mechanism of the SPY1ΔlytACaPi mineralization vaccine in terms of humoral and cellular immunity. In mice vaccinated subcutaneously, IgG titers in the SPY1ΔlytACaPi group were higher than those of the SPY1ΔlytA + alum group. This suggested that SPY1ΔlytACaPi not only induces an effective humoral immune response in subcutaneous-vaccinated mice, but the mineralized components of the mineralized strain have an adjuvant effect. However, our experimental results in mucosal vaccinated mice showed that SPY1ΔlytACaPi did not increase IgG level, this most likely due to the different modes of immunization.

In addition to humoral immunity, cellular immunity also plays an important role in antimicrobial infection. Proinflammatory cytokines such as IFN-γ, IL-4, IL-17A, and IL-10 play important roles in the immunization process against S. pneumoniae (29–34). Our results indicated that SPY1ΔlytACaPi significantly promoted the secretion of IL-17A and IL-10, compared with SPY1ΔlytA in mucosally vaccinated mice, suggesting that it could induce Th17 and Treg cell immune responses. However, IL-4 was not significantly induced in mice after immunization with mineralized strains, but IL-10 was elevated significantly. Because IL-10 is also a Th2-type cytokine as is IL-4, this indicated that the mineralized vaccine might also induce Th2 cell immune responses. However, there was no significant difference between SPY1ΔlytACaPi and SPY1ΔlytA + CT group suggesting the mineralized layer creates an adjuvant effect and can activate Th17 and Treg cell immune responses.

We have also studied the protective effect of SPY1ΔlytACaPi on nasal colonization of S. pneumoniae. Th17 cellular immune response plays an important role in this type of colonization by S. pneumoniae (34–36) and IL-4 is not involved (34). The results of our experiments showed that the bacterial loads in the nasal cavities of mice immunized with SPY1ΔlytACaPi were significantly lower than those of other groups.

FIGURE 5 | Humoral and cellular immune responses in mice induced by SPY1ΔlytACaPi vaccine. For mucosal immunization, C57BL/6 mice were immunized with choler toxin (CT), SPY1, SPY1ΔlytA, SPY1ΔlytA + CT, and SPY1ΔlytACaPi, respectively. For subcutaneous immunization, C57BL/6 mice was immunized with alum adjuvant, SPY1ΔlytAΔCaPi, and subcutaneous with alum adjuvant, phosphate-buffered saline (PBS), SPY1ΔlytA, SPY1ΔlytA + alum, and SPY1ΔlytACaPi. (A) IgG titters in serum were measured 1 week after mucosal (left) or subcutaneous (right) final immunization. One week after the last immunization, suspensions of splenocytes (1×10^5 cells/well) were cultured and exposed to 70% ethanol-killed SPY1 (equivalent to 10^7 CFU/ml) for 72 h at 37°C. The levels of cytokine of splenocytes from (B) mucosal and (C) subcutaneous immunized mice were determined by ELISA kits. *P < 0.05, **P < 0.01, ***P < 0.001.

FIGURE 6 | Immunization with SPY1ΔlytACaPi reduced pneumococcal colonization. Mice mucosally (A) or subcutaneously (B) immunized with indicated antigens (mucosal with choler toxin (CT), SPY1, SPY1ΔlytA, SPY1ΔlytA + CT, and SPY1ΔlytACaPi, and subcutaneous with alum adjuvant, phosphate-buffered saline (PBS), SPY1ΔlytA, SPY1ΔlytA + alum, and SPY1ΔlytACaPi) were intranasally challenged with Streptococcus pneumoniae serotype 19F (CMCC 31693, 1.5 x 10^8). Bacterial loads in nasal washes were determined three days postinfection. *P < 0.05; **P < 0.01.
lower than that of the non-mineralized vaccine group \((P < 0.01)\). Mechanistically this may be due to a greater Th17 cell immune response after mucosal immunization. Secretion of IL-17A into the nasal cavity recruited neutrophils that effectively removed the bacterial infection \((37)\).

In our study, we found that the colonization effect of SPY1\(\Delta lytA\)CaPi group bears comparison with non-mineralized vaccine groups in the presence of adjuvants (SPY1\(\Delta lytA + CT\) or SPY1\(\Delta lytA +\) alum). Familiar phenomenon was also observed in survival rates evaluation. These results suggested that the mineralized shell had an adjuvant effect. In addition, in mice vaccinated mucosally, the survival rates of the SPY1\(\Delta lytA\)CaPi group were significantly higher than those of SPY1\(\Delta lytA\) group, which were consistent with the results of cytokines. This indicated that mucosally vaccinated the mineralized strain could provide better protection against pneumococcal infections than the non-mineralized strain in mice.

In summary, we constructed a mineralized bacterial strain SPY1\(\Delta lytA\)CaPi and evaluated its thermal stability, immunoprotective effects, and immune protection mechanism. The mineralized shell increased bacterial stability. The protect effects of mineralized vaccine were superior to non-mineralized vaccine both in mucosal and subcutaneous vaccinations. The former induced mainly Th17 response while the later increased IgG levels. The results of this study lay the foundation for further research and development of \(S. pneumoniae\) vaccines.

**ETHICS STATEMENT**

All the animal experiments were done in accordance with the guidelines of the Institutional Animal Care and Use Committee of Chongqing Medical University.

**AUTHOR CONTRIBUTIONS**

WX and XZ designed the studies and wrote the paper. XZ and JC performed experiments about SPY1\(\Delta lytA\) mutant strain construction and mineralization. YW, HW, and YQ performed animal experiments. JW and YM analyzed data. YH, XZ, and YY provided advice in experiments.

**FUNDING**

This work was supported by the Natural Science Foundation of China (No. 81671639 to WX and 31270984 to WX).

**REFERENCES**

1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by \(S. pneumoniae\) in children younger than 5 years: global estimates. *Lancet* (2009) 374(9693):893–902. doi:10.1016/S0140-6736(09)61204-6

2. Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. *J Infect* (2014) 69(4):309–25. doi:10.1016/j.jinf.2014.06.006

3. World Health Organization. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007 – conclusions and recommendations. *Wkly Epidemiol Rec* (2008) 83(1):1–15.

4. World Health Organization. Pneumococcal vaccines. WHO position paper. 2012. *Wkly Epidemiol Rec* (2012) 14:129–44.

5. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med* (1991) 325(21):1453–60. doi:10.1056/NEJM19911123252101

6. Weinerberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet* (2011) 378:1962–73. doi:10.1016/S0140-6736(10)62225-8

7. Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, et al. Rapid pneumococcal evolution in response to clinical interventions. *Science* (2011) 331(6016):430–4. doi:10.1126/science.1198545

8. Malley R, Anderson PW. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. *Proc Natl Acad Sci U S A* (2012) 109(10):3623–7. doi:10.1073/pnas.1121383109

9. Wu KP, Yao R, Wang H, Pang D, Liu YS, Xu HM, et al. Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confers serotype independent protection against *S. pneumoniae* in mice. *Vaccine* (2014) 32:4179–88. doi:10.1016/j.vaccine.2014.05.019

10. Xu X, Wang H, Liu Y, Wang Y, Zeng L, Wu K, et al. Mucosal immunization with the live attenuated vaccine SPY1 induces humoral and Th1/Th17-regulatory T cell cellular immunity and protects against pneumococcal infection. *Infect Immun* (2015) 83(1):90–100. doi:10.1128/IAI.02334-14

11. Zeng L, Liu Y, Wang H, Liao P, Song Z, Gao S, et al. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against *S. pneumoniae* infection in young mice. *Vaccine* (2015) 33(8):1008–16. doi:10.1016/j.vaccine.2015.01.013

12. Zhang J, Pritchard E, Hu X, Valentin T, Panilaitis B, Fiorenzo G, et al. Stabilization of vaccines and antibiotics in silk and eliminating the cold.
chain. Proc Natl Acad Sci U S A (2012) 109(30):11981–6. doi:10.1073/pnas.1206210109
13. Hartgerink JD, Beniash E, Stupp SI. Self-assembly and mineralization of peptide amphiphile nanofibers. Science (2001) 294(5547):1684–8. doi:10.1126/science.1063187
14. Roy MD, Stanley SK, Amis EJ, Becker ML. Identification of a highly specific hydroxyapatite-binding peptide using phage display. Adv Mater (2008) 20(10):610–7. doi:10.1002/adma.200702322
15. Yao H, Dao M, Imholt T, Huang J, Wheeler K, Bonilla A, et al. Protection mechanisms of the iron-plated armor of a deep sea hydrothermal vent gastropod. Proc Natl Acad Sci U S A (2010) 107(3):987–92. doi:10.1073/pnas.0912988107
16. Hamm CE, Merkel R, Springer O, Jurkoje P, Maier C, Prechtel K, et al. Architecture and material properties of diatom shells provide effective mechanical protection. Nature (2003) 423(6925):841–3. doi:10.1038/nature01416
17. Wang G, Li X, Mo L, Chen W, Deng Y, Zhao H, et al. Eggshell-inspired biomineralization generates vaccines that do not require refrigeration. Angew Chem Int Ed Engl (2012) 51(42):10576–9. doi:10.1002/anie.201206154
18. Wang B, Liu P, Jiang W, Pan H, Xu X, Tang R. Yeast cells with an artificial mineral shell: protection and modification of living cells by biomimetic mineralization. Angew Chem Int Ed Engl (2008) 47(19):3560–4. doi:10.1002/anie.200704718
19. Wang G, Cao J, Chen DP, Xu WC, Chen TM, Xu SX, Luo JY, et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination: the key to pneumococcal disease. J Infect Dis (2004) 190(3):624–31. doi:10.1086/422329
20. Thanassi JA, Hartman-Neumann SL, Dougherty TJ, Dougherty BA, Pucci MJ. Identification of 113 conserved essential gene using a high-throughput gene disruption system in Streptococcus pneumonia. Nucleic Acids Res (2002) 30(14):3152–62. doi:10.1093/nar/gkf418
21. Claverys JP, Dintilhac A, Pestova EV, Martin B, Morrison DA. Construction and evaluation of new drug-resistance cassettes for gene disruption mutagenesis in Streptococcus pneumoniae, using an ami test platform. Gene (1995) 164(1):123–8. doi:10.1016/0378-1119(95)00485-O
22. Roche AM, King SJ, Weiser JN. Live attenuated "thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc Natl Acad Sci U S A (2013) 110(19):7619–24. doi:10.1073/pnas.1300233110
23. Cao J, Chen DP, Xu WC, Chen TM, Xu SX, Luo JY, et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination: the key to pneumococcal disease. J Infect Dis (2004) 190(3):624–31. doi:10.1086/422329
24. Ferreira DM, Darrieux M, Oliveira MLS, Leite LCC, Miyaji EN. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein A is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a response. J Immunol (2005) 170(1):438–44. doi:10.4049/jimmunol.170.1.438
25. Mellor P, Daniels R, Eberhardt A, Rönnlund D, Blom H, Widengren J, et al. LytA, major autolysin of Streptococcus pneumoniae, is required for nascent peptidoglycan. J Biol Chem (2012) 287:11018–29. doi:10.1074/jbc.M111.31858
26. Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis (2004) 4:144–54. doi:10.1016/S1473-3099(04)00398-7
27. Tan ACL, Mifsud EJ, Zeng W, Edenbergour K, McVernon J, Brown LE, et al. Intranasal administration of the TLR2 agonist Pam3Cys provides rapid protection against influenza in mice. Mol Pharm (2012) 9:2710–8. doi:10.1021/mp200757x
28. He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ. Calcium phosphate nanoparticle adjuvant. Clin Diag Lab Immunol (2000) 7(6):899–903.
29. He Q, Mitchell A, Morcol T, Bell SJ. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diag Lab Immunol (2002) 9(5):1021–4.
30. Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, et al. Toll-like receptor 2 participate in mediation of immune response in experimental pneumococcal meningitis. J Immunol (2003) 170(1):438–44. doi:10.4049/jimmunol.170.1.438
31. Albiger R, Sandgren A, Katsuragi H, Meyer-Hoffert U, Beiter K, Wartha F, et al. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol (2005) 7(11):1603–15. doi:10.1111/j.1462-5822.2005.00578.x
32. Van Rossum AMC, Lysenko ES, Weiser JN. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun (2005) 73(11):7718–26. doi:10.1128/IAI.73.11.7718-7726.2005
33. Malaviya R, Ikeda T, Ross E, Abroham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-a. Nature (1996) 381(6577):77–80. doi:10.1038/381077a0
34. Cruse G, Fernandes VE, de Salort J, Pankhania D, Marinas MS, Brewin H, et al. Human lung mast cells mediate pneumococcal response to activation by pneumolysin. J Immunol (2010) 184(12):7108–15. doi:10.4049/jimmunol.0900802
35. Jackson DC, Lau YF, Le T, Sugribier A, Deliyannis G, Cheers C, et al. A totally synthetic vaccine of generic structure that targets toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 101(43):15440–5. doi:10.1073/pnas.0407410101
36. Cheng C, Jain P, Bettai I, Pal S, Tifrè D, De la Maza LM. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Proc Natl Acad Sci U S A (2004) 101(3):11554–9. doi:10.1073/pnas.0407410101
37. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis (2004) 190(3):624–31. doi:10.1086/422329

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.